Pharmaceutical manufacturers of Oxytetracycline hydrochloride

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

We are the primary manufacturer of Avermectin worldwide and the leading producer of Ivermectin in Asia, with an annual production that constitutes half of the total in China. Additionally, we hold the top position as the producer for Tiamulin, Eprinomectin, and Emamectin Benzoate in China.

Hwail Pharm is a South Korean pharmaceutical company established in 1980. They operate in two main areas: Pharmaceutical Raw Materials: Hwail Pharm manufactures and distributes various ingredients used in the production of medications, including antitussives, expectorants, and anti-inflammatories. Finished Formulations: They also produce and sell finished pharmaceutical products, such as injection solutions like ceftazidime and cefoperazone. The company has its headquarters in Hwaseong, South Korea, and is a significant player in the South Korean pharmaceutical market. They prioritize quality and adhere to international standards in their manufacturing and distribution processes. Additionally, they offer food ingredients beyond pharmaceuticals.

Established in 1968, Fermic has grown to become one of the leading fermentation companies in Latin America. Accredited by the US FDA, Fermic specializes in the manufacturing of fermentation products such as APIs, with potassium clavulanate as its flagship product available in oral and sterile formulations. Additionally, Fermic offers contract manufacturing services for fermentation products including Active Pharmaceutical Ingredients and Enzymes.

Inner Mongolia Changsheng Pharmaceutical Co., Ltd. was established in the year 2003. The company is mainly engaged in the production and sale of APIs. The products made on the site include Amoxicillin, ampicillin, piperacillin, 6-aminopenicillanic acid, penicillin G potassium, and sulbactamic acid. Changsheng Pharma is accredited and approved by China NMPA, EDQM etc. for GMP compliance.

Founded in 1968, Sichuan Long March Pharmaceutical Co., Ltd. is located in Leshan City, a famous historical and cultural city in Southwest Sichuan Province. Long March, directly controlled by Sichuan Lanyan Investment Group Co., Ltd. (hereinafter referred to Lanyan Group), is a large antibiotic API production enterprise in Southwest China, which is the core enterprise of key medical pharmaceutical industry of Lanyan Group.

Yangzhou Liberty Pharmaceutical Co Ltd operates as an API manufacturer and a collaborative enterprise rooted in Yangzhou Pharmaceutical Co Ltd. In 2013, our firm took over Datong Tongxing Antibiotic Co Ltd in Shanxi Province, solidifying our position as the holding company. In addition to our current operations, we are dedicated to the development and manufacture of alternative fermentation raw materials. Leveraging an advanced quality control system, several of our products have successfully navigated rigorous assessments, including inspection by the US FDA, as well as securing COS, EU-GMP, and GMP certifications. Anhui Liberty Pharmaceutical Co Ltd and Datong Tongxing Antibiotic Co Ltd are also integral parts of our enterprise.